Registration

RESOLUTE-DC for MODEL MEDICINES

Firm
Client
Income
—
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

Supporting Model Medicines as it seeks federal funding to further develop, receive FDA approvals for, and begin manufacturing for their drug, MDL-001, which has been identified as a potential best-in-class, pan-antiviral drug with treatment paradigm changing potential. We are approaching congressional committees that authorize and fund HHS/NIH programs and DARPA (at DOD). We also are approaching political appointees in those agencies, as possible.

LobbyistCovered position, as disclosed
ADAM WILCZEWSKI New Chief of Staff, International Trade Administration

Health Issues HCR

Supporting Model Medicines as it seeks federal funding to further develop, receive FDA approvals for, and begin manufacturing for their drug, MDL-001, which has been identified as a potential best-in-class, pan-antiviral drug with treatment paradigm changing potential. We are approaching congressional committees that authorize and fund HHS/NIH programs and DARPA (at DOD). We also are approaching political appointees in those agencies, as possible.

LobbyistCovered position, as disclosed
ADAM WILCZEWSKI New Chief of Staff, International Trade Administration

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.